Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

L’impatto dell’esercizio preoperatorio e dell’ottimizzazione nutrizionale sugli esiti perioperatori per i pazienti sottoposti a trattamento per il cancro del retto: lo studio PROPEL

28 settembre 2026 aggiornato da: Jeffrey A. Meyerhardt, MD, Dana-Farber Cancer Institute

The purpose of this study is to determine the feasibility of a prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant chemotherapy and/or radiation, followed by surgical resection.

The names of the groups in this research study are:

  • Group A: Prehabilitation program
  • Group B: Usual Care

Panoramica dello studio

Descrizione dettagliata

This is a non-blinded, randomized control trial to determine the feasibility of a hybrid-model, prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant therapy (chemotherapy and/or radiation) before surgical resection. Investigators hope that prehabilitation will result in improved outcomes after surgery.

Participants will be randomized into one of the study groups: Group A: prehabilitation program, or Group B: usual care. Randomization means that a participant is placed into a group by chance.

The research study procedures include screening for eligibility, in-clinic visits, physical exams, exercise training, blood tests, and questionnaires.

It is expected that about 40 participants will take part in this research study.

Tipo di studio

Interventistico

Iscrizione (Stimato)

40

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Brigham and Women's Hospital
        • Contatto:
        • Investigatore principale:
          • Joel Goldberg, MD
      • Boston, Massachusetts, Stati Uniti, 02115
        • Reclutamento
        • Dana-Farber Cancer Institute
        • Investigatore principale:
          • Jeffrey Meyerhardt, MD
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age greater than or equal to 18 years at time of enrollment.
  • English-Speaking.
  • Diagnosis of clinical stage II-III rectal cancer.
  • Planned, ongoing or just completed neoadjuvant treatment, including either 1) chemoradiation, 2) total neoadjuvant therapy (TNT), or 3) chemotherapy only; and anticipated surgical resection to follow.
  • Able to understand the study procedures, agree to participate in the study program, and voluntarily provide informed consent.

Exclusion Criteria:

  • Distant metastatic disease known at the time of diagnosis.
  • Functional incapacity (i.e., incapable of performing exercise testing).
  • Comorbid conditions or cognitive/physical impairments that contraindicate exercise.
  • Currently undergoing treatment for a secondary primary tumor, in addition to primary rectal cancer.
  • Currently enrolled in a separate clinical trial that would prohibit them from performing the tasks instructed in this trial.
  • Currently participating in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month. This study targets insufficiently active persons to assess the effect of the described intervention, where additional exercise done regularly will contaminate the intervention effects.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Group A: Prehabilitation Program

Participants will be randomized in a 1:1 ratio using a permuted blocked design and stratified by neoadjuvant therapy received. Participants will complete the following:

  • In-clinic baseline visit with assessments
  • Virtual exercise sessions 3 days per week for 4 weeks.
  • IMN supplementation and daily multivitamin starting at 4 weeks of the preoperative phase.
  • Resection surgery per standard of care
  • In-clinic 30 day postoperative visit.

A hybrid-based, prehabilitation regimen comprised of nutritional optimization (multivitamin and protein supplement shake) and virtual, aerobic and resistance exercise sessions with clinical exercise physiologists. Virtual exercise sessions will be performed via a HIPAA-compliant videoconferencing platform or by phone call. Mini-exercise cycle ergometer, dumbbells, and resistance bands will be provided and delivered to participant. Heart rate monitors and wi-fi enable tablet will be provided if needed.

Nessun intervento: Group B: Usual Care

Participants will be randomized in a 1:1 ratio using a permuted blocked design and stratified by neoadjuvant therapy received. Participants will complete the following:

  • In-clinic baseline visit with assessments
  • Resection surgery per standard of care
  • In-clinic 30 day postoperative visit
  • After completion of the study period, participants will be offered exercise equipment with an exercise instruction booklet.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Enrollment Rate
Lasso di tempo: Baseline

The proportion of eligible individuals that are enrolled to the study. Feasibility of the intervention is defined as an enrollment rate of greater than 10% of approached, eligible participants.

Baseline

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Adherence Rate to the Prehabilitation Program
Lasso di tempo: At post-intervention (approximately Week 4)

The number of intervention assessments completed by participants in Group A. Feasibility of the intervention is defined as at least 50% of participants adhering to at least 50% of the prescribed assessments of the prehabilitation program.

At post-intervention (approximately Week 4)
Completion Rate of Physical Function Testing (Group A)
Lasso di tempo: At post-intervention (approximately Week 4)

Defined as the number of testing assessments (resting blood pressure, measure of cardiorespiratory fitness, Short Physical Performance Battery, muscular strength, and anthropometric measures) completed by participants.

At post-intervention (approximately Week 4)
Completion Rate of Physical Function Testing (Group B)
Lasso di tempo: At post-intervention (approximately Week 4)

Defined as the number of testing assessments (resting blood pressure, measure of cardiorespiratory fitness, Short Physical Performance Battery, muscular strength, and anthropometric measures) completed by participants.

At post-intervention (approximately Week 4)
Completion Rate of Questionnaire Assessments
Lasso di tempo: At baseline and the postoperative visit (approximately Week 9)

Defined as the number of questionnaires completed by all participants.

At baseline and the postoperative visit (approximately Week 9)
Participant Fall Rate (Group A)
Lasso di tempo: At post-intervention (approximately Week 4)

Defined as the number of falls attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Participant Fall Rate (Group B)
Lasso di tempo: At post-intervention (approximately Week 4)

Defined as the number of falls attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Rate of Hospitalization (Group A)
Lasso di tempo: At post-intervention (approximately Week 4)

Defined as the number of hospitalizations attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Rate of Hospitalization (Group B)
Lasso di tempo: At post-intervention (approximately Week 4)

Defined as the number of hospitalizations attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Rate of Musculoskeletal Injury (Group A)
Lasso di tempo: At post-intervention (approximately Week 4)

Defined as the number of musculoskeletal injuries attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Rate of Musculoskeletal Injury (Group B)
Lasso di tempo: At post-intervention (approximately Week 4)

Defined as the number of musculoskeletal injuries attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Change in Resting Blood Pressure from Baseline to Post-Intervention
Lasso di tempo: From baseline to post-operative visit (approximately week 9)

Assessed by resting blood pressure. The average systolic blood pressure (of two measurements from each arm) will be recorded.

From baseline to post-operative visit (approximately week 9)
Change in Cardiorespiratory Fitness from Baseline to Post-Intervention
Lasso di tempo: From baseline to post-operative visit (approximately week 9)

Assessed by VO2peak by a graded maximal (or submaximal if equipment is unavailable) cycle exercise stress test. VO2peak is defined as the highest values of oxygen uptake averaged among every 30-second interval during the test. VO2peak will be reported in both relative (ml·kg-1·min-1) and absolute (L/min) terms.

From baseline to post-operative visit (approximately week 9)
Change in Short Physical Performance Battery (SPPB) Score from Baseline to Post-Intervention
Lasso di tempo: From baseline to post-operative visit (approximately week 9)

Assessed by the Short Physical Performance Battery (SPPB) which is comprised of three sections: 1) balance with feet together, semi tandem, and full tandem is held for up to 10 seconds with no support and measure in seconds. Scores are summed for the measure of balance for a range of 0 to 30 seconds; 2) usual gait speed over four meters is timed (seconds); and 3) chair stand where the time(s) to complete five chair sit-to-stands is recorded. Each of the three performance measures is assigned a score ranging from 0 to 4, with 4 indicating highest level of performance and 0 indicating inability to complete test. A summary score ranging from 0 (worst performers) to 12 (best performers) is calculated by adding walking speed, chair stands and balance scores.

From baseline to post-operative visit (approximately week 9)
Change in Muscle Strength from Baseline to Post-Intervention
Lasso di tempo: From baseline to post-operative visit (approximately week 9)

The 1RM (repetition maximum) will be estimated from 10RM muscle strength tests on two exercises: 1) leg press, 2) chest press. 1RM values will be calculated and reported using validated equations.

From baseline to post-operative visit (approximately week 9)
Change in Height from Baseline to Post-Intervention
Lasso di tempo: From baseline to post-operative visit (approximately week 9)

Height will be measured using a stadiometer, rounding up to the nearest 0.1 cm

From baseline to post-operative visit (approximately week 9)
Change in Weight from Baseline to Post-Intervention
Lasso di tempo: From baseline to post-operative visit (approximately week 9)

Assessed by weight, rounding up to the nearest 0.1 kg.

From baseline to post-operative visit (approximately week 9)
Change in Waist Circumference from Baseline to Post-Intervention
Lasso di tempo: From baseline to post-operative visit (approximately week 9)

Waist circumference will be measured, rounding up to the nearest 0.1cm.

From baseline to post-operative visit (approximately week 9)
Change in Hip Circumference from Baseline to Post-Intervention
Lasso di tempo: From baseline to post-operative visit (approximately week 9)

Hip circumference will be measured, rounding up to the nearest 0.1cm.

From baseline to post-operative visit (approximately week 9)
Change in Body Mass Index from Baseline to Post-Intervention
Lasso di tempo: From baseline to post-operative visit (approximately week 9)

Body composition will be assessed via bioelectrical impedance using a validated device. The device will estimate body fat using an algorithm based on participant age, sex, height, and body weight.

From baseline to post-operative visit (approximately week 9)
Change in Nutritional Status from Baseline to Post-Surgery (Group A)
Lasso di tempo: From baseline to postoperative visit, up to 9 weeks

Assessed by the Perioperative Nutrition Score (PONS), a validated screening questionnaire that assists in determining risk of malnutrition in the perioperative setting. This is assessed via 1) Body mass index (BMI), which can be calculated through the participant's anthropomorphic measurements, 2) self-reported unplanned changes in weight or decrease in dietary intake, or 3) preoperative albumin level.

From baseline to postoperative visit, up to 9 weeks
Change in Nutritional Status from Baseline to Post-Surgery (Group B)
Lasso di tempo: From baseline to postoperative visit, up to 9 weeks

Assessed by the Perioperative Nutrition Score (PONS), a validated screening questionnaire that assists in determining risk of malnutrition in the perioperative setting. This is assessed via 1) Body mass index (BMI), which can be calculated through the participant's anthropomorphic measurements, 2) self-reported unplanned changes in weight or decrease in dietary intake, or 3) preoperative albumin level.

From baseline to postoperative visit, up to 9 weeks
Change in Quality of Life from Baseline to Post-Surgery (Group A)
Lasso di tempo: From baseline to postoperative visit, up to 9 weeks

Assessed by the European Organization for Research and Treatment of Cancer's (EORTC's) Quality of Life (QOL) core questionnaire (QLQ C-30), a validated, 30-item instrument designed to quantify and measure QOL in cancer participants. Questions are rated on a four point scale from 1 "Not at all" to 4 "Very much. All items have a score range from 0 to 100 points. A higher score represents better function and a higher quality of life.

From baseline to postoperative visit, up to 9 weeks
Change in Quality of Life from Baseline to Post-Surgery (Group B)
Lasso di tempo: From baseline to postoperative visit, up to 9 weeks

Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality.

From baseline to postoperative visit, up to 9 weeks
Change in Pittsburgh Sleep Quality Index (PSQI) Score from Baseline to Post-Surgery (Group A)
Lasso di tempo: From baseline to postoperative visit, up to 9 weeks

Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality.

From baseline to postoperative visit, up to 9 weeks
Change in PSQI Score from Baseline to Post-Surgery (Group B)
Lasso di tempo: From baseline to postoperative visit, up to 9 weeks

Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality.

From baseline to postoperative visit, up to 9 weeks
Change in Clinical Frailty Scale (CFS) Score from Baseline to Post-Surgery (Group A)
Lasso di tempo: From baseline to postoperative visit, up to 9 weeks

Assessed by the Clinical Frailty Scale (CFS), which consists of 9 questions assessing specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill).

From baseline to postoperative visit, up to 9 weeks
Change in Clinical Frailty Scale (CFS) Score from Baseline to Post-Surgery (Group B)
Lasso di tempo: From baseline to postoperative visit, up to 9 weeks

Assessed by the Clinical Frailty Scale (CFS), which consists of 9 questions assessing specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill).

From baseline to postoperative visit, up to 9 weeks
Length of Hospitalization Post-Surgery (Group A)
Lasso di tempo: 30 Days

Defined as the number of days of hospitalization post-surgery.

30 Days
Length of Hospitalization Post-Surgery (Group B)
Lasso di tempo: 30 Days

Defined as the number of days of hospitalization post-surgery.

30 Days
Time To Return of Bowel Function Post-Surgery (Group A)
Lasso di tempo: 30 Days

Defined as the number of days to a return of bowl function post-surgery.

30 Days
Time To Return of Bowel Function Post-Surgery (Group B)
Lasso di tempo: 30 Days

Defined as the number of days to a return of bowl function post-surgery.

30 Days
Discharge Disposition (Group B)
Lasso di tempo: 30 Days

Defined as participant disposition post-surgery: discharge to home, inpatient rehabilitation facility, or other. Data will be summarized using descriptive statistics.

30 Days
Discharge Disposition (Group A)
Lasso di tempo: 30 Days

Defined as participant disposition post-surgery: discharge to home, inpatient rehabilitation facility, or other. Data will be summarized using descriptive statistics.

30 Days

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Jeffrey Meyerhardt, MD, MPH, Dana-Farber Cancer Institute

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 dicembre 2024

Completamento primario (Stimato)

1 luglio 2027

Completamento dello studio (Stimato)

30 dicembre 2027

Date di iscrizione allo studio

Primo inviato

16 agosto 2024

Primo inviato che soddisfa i criteri di controllo qualità

19 agosto 2024

Primo Inserito (Effettivo)

21 agosto 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

30 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Periodo di condivisione IPD

Data can be shared no earlier than 1 year following the date of publication

Criteri di accesso alla condivisione IPD

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi